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Abstract This review provides recommendations for
anesthesia providers who may not yet have quantitative
monitoring and sugammadex available and thus are pro-
viding care within the limitations of a conventional
peripheral nerve stimulator (PNS) and neostigmine. In
order to achieve best results, the provider needs to under-
stand the limitations of the PNS. The PNS should be
applied properly and early. All overdosing of neuromus-
cular blocking drugs should be avoided and the intraoper-
ative neuromuscular blockade should be maintained only
as deep as necessary. The adductor pollicis is the gold
standard site and must be used for the pre-reversal
assessment, also when the ulnar nerve and thumb were not
accessible intraoperatively. Spontaneous recovery should
be maximized and neostigmine should be administered
after a TOF count of 4 has been confirmed at the adductor
pollicis. Extubation should not occur within 10 min after
administration of an appropriate dose of neostigmine.
Keywords Residual neuromuscular blockade  Residual
paralysis  Neuromuscular monitoring  Qualitative
neuromuscular monitoring  Neuromuscular block
reversal  Neuromuscular block antagonism
Introduction
Historically, anesthesia providers have had substantial
difficulty using conventional peripheral nerve stimulators
(PNS) to achieve a low incidence of residual neuromus-
cular blockade (NMB). In a meta-analysis which aimed to
examine the effect of intraoperative neuromuscular mon-
itoring on the incidence of postoperative residual NMB,
the authors ‘‘could not demonstrate that the use of an
intraoperative neuromuscular function monitor decreased
the incidence of postoperative residual neuromuscular
blockade’’ [1]. Multiple studies that have reported on the
use of conventional PNS and intermediate-acting neuro-
muscular blocking drugs (NMBDs) have documented a
high incidence of residual NMB [2–4]. A more recent and
well-conducted multicenter observational study reported a
63.5 % incidence of residual paralysis at the time of
extubation [5••]. Taken together, these results indicate that
reducing the incidence of residual NMB is a great chal-
lenge when working with conventional PNS and choli-
nesterase inhibitors. This review provides
recommendations for anesthesia providers who may not
yet have quantitative neuromuscular monitoring and rely
on monitoring with conventional qualitative peripheral
nerve stimulators (PNS). The authors summarize what
they believe is the best practice with a qualitative stan-
dard PNS monitor and neostigmine. In order to highlight
the differences between qualitative and quantitative
monitors, we briefly discuss also the latter. It is assumed
that the reader is somewhat familiar with TOF monitoring
and the TOF ratio and that long-acting muscle relaxants
such as pancuronium are no longer preferred due to their
significant association with residual neuromuscular
blockade.
This article is part of the Topical Collection on Neuromuscular
Blockade.
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Limitations of Conventional Peripheral Nerve
Stimulators
Conventional nerve stimulators may also be referred to as
subjective, simple, or qualitative. A major limitation of a
qualitative PNS monitor is that it cannot confirm that
reversal is successful [6], i.e., the absence of residual
paralysis, which is currently defined as a train-of-four
(TOF) ratio (the ratio of the amplitudes of the fourth twitch
to the first twitch, T4:T1)\ 0.9 at the ulnar nerve/adductor
pollicis [7]. Qualitative PNS do not provide an objective,
quantitative assessment of the amplitudes of the twitch
heights, but rather rely on subjective visual or tactile
assessment of the relative strength of the twitches.
Despite this limitation, anesthesia providers who care-
fully apply and thoroughly understand the limitations of a
qualitative PNS can improve management of NMBDs. Most
importantly, by using the qualitative PNS monitor to guide
the timing for pharmacological reversal, the incidence and
severity of residual paralysis can be reduced. Thiswas shown
by Kopman et al. in 2004 when they reported the results of
using a protocol for muscle relaxant and subsequent
neostigmine administration (0.05 mg/kg) that included
reversal at a TOF count of 2 [8]. Patients received cisa-
tracurium or rocuronium and only 2 of 60 patients had TOF
ratios\0.70, 15 min after reversal. To further improve on
these results with the aim of reaching the updated threshold
TOF ratio of 0.9, while still working within the limitations of
PNS and neostigmine, it is necessary to confirm a higher
level of spontaneous recovery prior to reversal.
Start Monitoring Early
The PNS should be applied early after anesthetic induction
and before muscle relaxants have been administered. The
electrodes should be placed over the ulnar nerve near the
wrist. The distal black (negative) electrode should be
placed near the wrist crease and the proximal red (positive)
electrode should be placed 3–6 cm proximal to the black
electrode along the path of the ulnar nerve. The PNS
should be able to display the stimulating current, which
should be at least 50–60 mA [9]. The hand and fingers
should be immobilized while the thumb should be able to
move freely. We recommend tactile assessment which is
performed by holding the thumb in full abduction and the
evoked twitch response is evaluated at the distal thumb
phalanx in the direction of the adductor pollicis contraction
(the trajectory of this contraction may vary from patient to
patient) [10]. Early use of the qualitative PNS monitor
immediately after induction of anesthesia and prior to
administration of neuromuscular blockade allows
confirmation of proper placement of electrodes and func-
tioning of the PNS and helps to prevent the situation where
the anesthesia provider finds no twitch response at the end
of the surgical procedure and may be in doubt whether the
monitor works properly.
An additional important benefit of early monitoring is
early identification of so-called outliers. There is great
inter-patient variation in response to NMBDs, and we refer
to the patients who have a substantially prolonged effect
from usual doses of NMBDs as outliers. These patients are
at increased risk of residual paralysis. They can be iden-
tified by a slower than expected reappearance of twitches
after the initial intubating dose of NMBD [11]. When such
patients are identified, it is important to monitor them
closely and to reduce each incremental dose in order to
avoid accumulation and a prolonged duration of the block.
When an outlier has been identified and anesthesia is
maintained with a potent inhalational agent, it may be
reasonable to consider conversion to total intravenous
anesthesia (TIVA) as reversal with neostigmine under
TIVA is more predictable compared to reversal in the
context of inhalational anesthesia [12]. This is consistent
with volatile anesthetics potentiating the effects (prolong
duration of action and recovery) of nondepolarizing muscle
relaxants. Outlier patients may also make good candidates
for sugammadex, if this drug is available.
Site of Monitoring
After baselineTOFhasbeenestablishedover theulnar nerve as
described previously, a more accessible site for qualitative
PNS monitoring may need to be chosen depending on the
procedure and positioning of the arms. When the adductor
pollicis is unavailable bilaterally, the next best site for the
evaluation is the great toe twitch with stimulation of the pos-
terior tibial nerve, if it can be easily and safely accessed and
monitored. Several studies have compared posterior tibial and
ulnar nerve stimulation and have found a more rapid recovery
of theTOF response at the great toe [13–17].Monitoring of the
great toe may, therefore, result in a relative underestimation of
the neuromuscular blockade and it is important to move
monitoring to the adductor pollicis for the pre-reversal
assessment when the arms become accessible again at the end
of the surgical procedure. Facial nerve stimulation and eval-
uationof eyemuscle twitcheshavebeen shown tobe unreliable
and associated with a five-fold increase in the incidence and
severity of residual paralysis [18•]. Muscles surrounding the
eye, which are stimulated in facial nerve monitoring, are rel-
atively resistant to NMBDs compared to the adductor pollicis
and studies have consistently documented an earlier recovery
of twitches at this site [19–27]. It is possible that direct muscle
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stimulation, circumventing the neuromuscular block, plays a
role in some cases. Importantly, if an alternate site other than
the ulnar nerve/adductor pollicis is used, expert researchers
have suggested tomovemonitoring to theulnar nerve/adductor
pollicis at the end of the procedure and prior to administration
of neostigmine to properly assess the degree of neuromuscular
blockade [28•].
Depth of Neuromuscular Blockade
The primary purpose of intraoperative administration of
NMBDs is to provide optimal surgical conditions. The
appropriate depth of intraoperative neuromuscular block is
highly variable and depends on many factors including the
type and phase of the surgical procedure, individual patient
and surgeon, and also on the anesthetic technique. The
block should not be deeper than what is required, and for
many procedures a TOF count of 1–2 is appropriate. For
lower abdominal surgeries, there is rarely a need to
maintain a deep block [29]. The required depth of block is
a clinical judgment based on several factors. Optimal
adjustment of the depth of the block requires effective
communication with the surgeon regarding his/her
requirement for intraoperative muscle relaxation. If the
block is too deep for TOF monitoring, i.e., there are no
twitches in the TOF response, then post-tetanic count
(PTC) should be used for monitoring. This is a mode that
takes advantage of post-tetanic facilitation and is per-
formed as follows: a 50 Hz tetanic stimulus is given for
5 s, this is followed by a 3-s pause after which single twitch
stimulation at 1 Hz (one twitch per second) is started. The
PTC is equal to the number of twitches counted. A PTC of
1 or 2 reflects a very deep block and virtually guarantees
patient immobility in cases where this is important, e.g., in
certain neurosurgical and open eye surgical procedures.
There is no convincing evidence that a deep block is of
benefit in laparoscopic surgery [30], and although a period
of PTC = 0 may occur after the intubating dose has been
administered, there is rarely a need to maintain a block that
is deeper than PTC = 1. When rocuronium is used, the first
twitch in the TOF can be expected to appear when the PTC
reaches approximately 10 (range 6–16).
Use of the PNS at Time of Reversal
When anesthesia providers subjectively assess the twitch
response of the adductor pollicis to ulnar nerve stimulation,
they are not reliably able to identify fade when the TOF
ratio exceeds 0.4 [6]. This means that even when the
amplitude of the 4th twitch is only half of the amplitude of
the first twitch, and the TOF ratio is 0.50, we perceive this
as four equal twitches and fail to detect the fade. When
using a qualitative PNS monitor, the TOF ratio ranging
from 0.40 to 0.90 has therefore been referred to as ‘‘the
zone of blind paralysis’’ [31]. The main benefit of a
quantitative nerve stimulator is that it can reliably and
quantitatively measure TOF ratios throughout this entire
range. Although the method of delivering tetanic stimula-
tion for 5 s at 100 Hz with the qualitative PNS monitor has
been demonstrated to detect fade at TOF ratios of 0.8–0.89,
its reliability is significantly less than that of a quantitative
PNS monitor to detect residual paralysis, and it can cause a
mild degree of fade itself [32]. Additionally, the high
stimulation frequency used for this method is also painful
for an awake or nearly awake patient, making its use
restricted to deeper levels of anesthesia.
When a quantitative PNS monitor is not available and
we use a qualitative PNS monitor, it is critical to maximize
the chances of a successful reversal. This is most reliably
accomplished by confirming an adequate level of sponta-
neous recovery prior to administration of neostigmine. This
may be considered the most critical aspect of management
when aiming to prevent residual paralysis while using a
qualitative PNS monitor and neostigmine.
Reversal at a TOF Count of 4 At the Adductor
Pollicis
Many providers were taught in training to administer
neostigmine with only one or two twitches present. How-
ever, several studies have led to the updated recommen-
dations to administer neostigmine only after the 4th twitch
has reappeared [12, 28•, 31, 33–35]). In fact, a successful
reversal to TOF ratio of C0.9 is not guaranteed even when
neostigmine is administered at a TOF count of 4; but, the
odds of a successful reversal are significantly improved
with this approach compared to when neostigmine is
administered at a lower degree of spontaneous recovery.
Kirkegaard et al. reported on the likely outcome from
reversal at the various TOF counts [33]. When giving
neostigmine with only the first twitch present, the odds of
achieving a TOF ratio of 0.9 in 10 min was zero and the
odds of getting a TOF ratio of at least 0.8 was 0.07. The
odds of achieving a TOF ratio of 0.8 in 10 min increased to
2.0 when neostigmine administration was delayed until the
fourth twitch had reappeared. This means that relative to a
patient who received neostigmine with a TOF count of 1, a
patient who receives neostigmine with a TOF count of 4 is
30 times more likely to achieve a TOF ratio of C0.8 in
10 min. Kim et al. also reported data strongly supporting
the advantage of reversing from TOF count of 4 (Fig. 1)
[12]. If spontaneous recovery is allowed to progress until
qualitative visual or tactile assessment of fade in the TOF
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disappears before neostigmine is administered (i.e., the
TOF ratio is expected to be at least 0.4), the odds of a
successful reversal become excellent as long as the
neostigmine dose is appropriately adjusted [36, 37]. The
dose of neostigmine should be reduced and not exceed
20–25 mcg/kg when no fade is observed with qualitative
TOF monitoring.
If the TOF count is 3 or less, the patient should be kept
anesthetized or deeply sedated until the 4th twitch is
clearly present [31, 35]. It is understandable that delaying
reversal (and thereby also delaying the subsequent emer-
gence and extubation), while first awaiting the return of the
4th twitch, will often be considered inconvenient. Of
course, avoiding all overdosing will help ensure that the
blockade is not unnecessarily deep at the end of the sur-
gical procedure. This includes careful dose adjustment of
NMBDs for age, gender, obesity, as well as only judicious
administration of incremental doses towards the end of the
surgical procedure [38, 39•, 40–42]. It may also be helpful
to educate all members of the surgical and perioperative
teams about fundamentals of safe management of NMBDs
to increase acceptance of this critical step of awaiting
adequate spontaneous recovery. Return of spontaneous
ventilation and normal tidal volumes should not be used for
timing of pharmacologic reversal as intubated patients
often have adequate ventilation despite low TOF counts.
An earlier reversal, such as at TOF counts of 1 to 3, will
routinely yield a TOF response with no fade at 10 min after
reversal, however without a quantitative monitor there is no
way of confirming that the reversal was successful. Patients
who are reversed at lower TOF counts while receiving
volatile anesthetics are more likely to end up in the zone of
blind paralysis (i.e., TOF ratio 0.4–0.9) than to achieve a
TOF ratio of C0.9 at 10 min after neostigmine [12, 43••].
Thus, reversal at low TOF counts often leads to low TOF
ratios which are not adequate for a safe extubation.
Increasing number of TOF twitches prior to reversal cor-
relates with a decreasing incidence and severity of residual
paralysis, and a decreased incidence of postoperative pul-
monary complications such as atelectasis and pneumonia
[7]. Every attempt to maximize reversal should be used in
patients with known or anticipated airway or pulmonary
impairment.
After administering neostigmine, it is important to allow
a sufficient amount of time prior to extubation. It may take
as much as 10 min for neostigmine’s peak effect to occur
[44, 45]. Patients who are successfully reversed should
have no fade with double burst stimulation or tetanic
stimulation at 50 Hz [46].
However, the use of tetanic stimulation is not the most
sensitive approach to detecting residual paralysis. Clinical
tests (head lift, hand grip, etc.) are not adequate to rule out
residual paralysis, either [47].
Anesthesiologists who use a quantitative monitor can
take a different approach from the one recommended for
use with a PNS. In this case, neostigmine can be admin-
istered at a lower TOF count of 1 or 2. While it would be
expected that reversal to a TOF ratio of 0.9 often takes
20 min or even longer, the quantitative monitor eliminates
the problem of the zone of blind paralysis and the patient
can be accurately monitored throughout. In some cases,
reversal will occur more quickly, and when this is con-
firmed with the quantitative monitor, extubation can be
safely performed without delay. Quantitative monitoring
has proved to be not only efficacious but also effective [48–
51]. Currently, the most widely available monitor is the
TOF-Watch which is based on acceleromyography. Cal-
ibration of this monitor is easily performed in less than 30 s
and improves its accuracy. It is performed after induction
of general anesthesia but before administration of NMBDs.
Measurements often show some variability and it is
therefore customary to perform several measurements until
two consecutive measurements are within 10 % and then to
average these. The monitor works best when applied to a
freely moving thumb, and devices have been developed to
protect the thumb from external disturbances during sur-
gery. If a freely moving thumb is not available intraoper-
atively, the monitor can be used at alternate sites but should
be moved to the ulnar nerve/adductor pollicis when this site
becomes available at the end of the case. As mentioned,
reversal can be administered at lower TOF counts with the
quantitative PNS monitors as the TOF ratio can be assessed
continuously to ensure a TOF ratio equal to or greater than
0.9 prior to extubation. When all operating rooms in an
anesthesia department were equipped with these monitors,
the incidence of residual paralysis declined continuously
over a 9-year period from 62 % to just 3 % [48]. This
Fig. 1 Percent of patients with recovery greater than train-of-four
(TOF) Ratio of 0.9 at 10 min after neostigmine (70 mcg/kg)
administration during propofol- or sevoflurane-based anesthesia. Bar
graphs are based on data reported by [12]
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improvement was accomplished while the only reversal
agent available was neostigmine.
Conclusions
While optimal management of NMBDs requires a quanti-
tative monitor, this review provides recommendations also
for anesthesia providers who have access only to conven-
tional qualitative monitoring.
The PNS should be used throughout the case to help the
anesthesia provider to titrate and monitor the required
intraoperative relaxation but most importantly to confirm
adequate spontaneous recovery prior to reversal with
neostigmine. The best location for monitoring is the ulnar
nerve/adductor pollicis and if a different site has been used
intraoperatively, monitoring should be moved to the ulnar
nerve/adductor pollicis prior to reversal. The return of 4
twitches at the adductor pollicis should be confirmed prior
to administering neostigmine. When fade is absent in the
TOF, the neostigmine dose should be adjusted and not
exceed 25 mcg/kg. While following the recommendations
in this article will reduce the incidence and severity of
residual paralysis, only a quantitative monitor allows for
definitive confirmation of full recovery from the effects of
muscle relaxants prior to extubation.
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